Suscribirse

HYPERCOAGULABLE STATES - 04/09/11

Doi : 10.1016/S0889-8588(05)70138-6 
Terence Whiteman, MD *, Houria I. Hassouna, MD, PhD *

Resumen

The hypercoagulable state places an individual at risk for, but does not in itself inevitably lead to, thrombosis. This article focuses on the mechanisms in the hypercoagulable state that enhance and maintain the production of thrombin in circulating blood while preventing its progression to thrombosis. These mechanisms include (1) reactions that produce thrombin from prothrombin, (2) feedback-loop mechanisms that affect the rate of thrombin production from prothrombin, and (3) the inactivation of thrombin in blood. The fibrinolytic system is involved in clot lysis but not in thrombin production and inactivation.

The hypercoagulable state has been defined as the potential to develop thrombosis in association with hereditary and noninherited genetic mutations and acquired disorders.2, 3, 4, 5, 6, 9, 10, 13, 19, 31, 39, 40, 45, 46, 47 The most commonly encountered disorders include

1
Genetic disorders of the hemostatic system:
Heterozygote antithrombin, protein C, and protein S nonsense mutations associated with decreased protein levels and activity10, 13, 31, 58
Abnormal clotting Factor V that resists proteolytic degradation by protein C8, 10
Heterozygote antithrombin, protein C, and protein S missense mutations (Missense mutations are characterized by normal protein levels and decreased anticoagulant activity.)16, 31
Compound heterozygote missense mutations involving both protein C and S16
Heterozygote mutations involving both Factor V Leiden mutation and protein C, protein S, or antithrombin13, 25
Inherited regional fibrinogen variants that decrease the rate of fibrin polymerization.21, 27 The physiologic pathway for thrombin inactivation is by specific binding to fibrin and incorporation into the fibrin clot. Fibrin produced from variant forms of fibrinogen does not effectively incorporate thrombin into clots.
Vascular malformations, congenital heart disease23
2
Risk factors associated with other genetic disorders
Diabetes
Polycythemia rubra vera
Sickle cell disease47
Thalassemia
Elevated ⍺-lipoprotein
Homocystinemia50
Hypertriglyceridemia
Chronic renal failure
Obstructive pulmonary disease
Paroxysmal nocturnal hemoglobinuria
3
Select acquired risk factors
Physiologic factors, including neonatal and postpartum states and pregnancy
Acquired coagulation and platelet disorders,5, 14, 15, 23 including thrombocytosis, abnormal fibrinogen variants, lupus anticoagulant, and antiphospholipid antibodies
Acquired antithrombin, protein C, or protein S deficiencies
Cardiovascular conditions,23, 33, 38, 40, 43 including mitral valve prolapse, heart failure, prosthetic heart valves, atrial fibrillation, hypertension with elevated angiotensin II, injured vessel wall, valvular insufficiency, abdominal aortic surgery, angioplasty, coronary bypass, central venous catheters, other indwelling vascular access devices, cardiopulmonary bypass2, 3, 4, 5, 37, 40, 46, 47, 51, 54
Therapeutic agents: oral contraceptives,43, 46 androgens, l-asparaginase, warfarin, thrombolytic therapy,17, 54, 63 and Factor IX concentrates
Surgical intervention: hepatic resections, gynecologic surgery, hip and knee replacements, laparoscopic cholecystectomy
Malignancies: acute promyelocytic leukemia, pancreatic and prostate cancers, metastatic tumors
Infections: gram-negative sepsis, acute pancreatitis
Nephrotic syndrome, cerebral infarcts37
These conditions are summarized in the following box.

Genetic Disorders Associated with Hypercoagulability


    Hemostatic System Other Systems Antithrombin Diabetes Protein C Polycythemia rubra vera Protein S Sickle cell anemia Abnormal clotting Factor V Congenital heart disease Fibrinogen variants Thalassemia Elevated lipoprotein ⍺ Homocystinemia Hypertriglyceridemia Paroxysmal nocturnal hemoglobinuria

    Hemostatic System Other Systems 
Antithrombin Diabetes 
Protein C Polycythemia rubra vera 
Protein S Sickle cell anemia 
Abnormal clotting Factor V Congenital heart disease 
Fibrinogen variants Thalassemia 
 Elevated lipoprotein ⍺ 
 Homocystinemia 
 Hypertriglyceridemia 
 Paroxysmal nocturnal hemoglobinuria 

The most intriguing aspect of the hypercoagulable states, and one which has received little attention, is the low frequency with which they are associated with thrombosis.46 For example, in pregnancy and other acquired and inherited hypercoagulable states, the calculated incidence of associated thrombosis, although slightly higher than in the general population, is less than 10%. This article provides information needed for the diagnosis and management of the hypercoagulable patient. It is divided in three sections: (1) a review of the regulatory systems that govern the hemostatic state; (2) a clinical presentation of the hypercoagulable anticoagulant deficiency genotype and the more common phenotype associated with disseminated intravascular coagulation; and (3) molecular markers.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Houria I. Hassouna, MD, PhD, Department of Medicine, B-239 Clinical Center, Michigan State University, East Lansing, MI 48824–1313, e-mail: hassouna@msu.edu


© 2000  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.© 1986  © 1994 
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 14 - N° 2

P. 355-377 - avril 2000 Regresar al número
Artículo precedente Artículo precedente
  • A COMPREHENSIVE REVIEW OF VITAMIN K AND VITAMIN K ANTAGONISTS
  • Cees Vermeer, Leon J. Schurgers
| Artículo siguiente Artículo siguiente
  • SCREENING FOR RISK FACTORS FOR THROMBOSIS USING A NEW GENERATION OF ASSAYS DEVELOPED TO EVALUATE THE FUNCTIONALITY OF THE PROTEIN C ANTICOAGULANT PATHWAY
  • Pierre Toulon, Patricia Perez

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.